Rituxan deaths reported to FDA

Share this article:
The deaths of two women being treated with Genentech's Rituxan (rituximab) for systemic lupus erythematosus have been reported to the FDA. The agency is working with the company to obtain additional info and to strengthen the warnings in the product labeling.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.